- Home
- BIIB vs LII Comparison
BIIB vs LII Comparison
Compare BIIB & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- LII
- Stock Information
- Founded
- BIIB 1978
- LII 1895
- Country
- BIIB United States
- LII United States
- Employees
- BIIB 7605
- LII N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- LII Industrial Machinery/Components
- Sector
- BIIB Health Care
- LII Industrials
- Exchange
- BIIB Nasdaq
- LII Nasdaq
- Market Cap
- BIIB 20.6B
- LII 22.4B
- IPO Year
- BIIB 1991
- LII 1999
- Fundamental
- Price
- BIIB $140.60
- LII $614.04
- Analyst Decision
- BIIB Buy
- LII Hold
- Analyst Count
- BIIB 27
- LII 12
- Target Price
- BIIB $220.50
- LII $613.91
- AVG Volume (30 Days)
- BIIB 1.5M
- LII 434.5K
- Earning Date
- BIIB 02-12-2025
- LII 01-29-2025
- Dividend Yield
- BIIB N/A
- LII 0.75%
- EPS Growth
- BIIB 40.28
- LII 36.28
- EPS
- BIIB 11.18
- LII 22.54
- Revenue
- BIIB $9,675,900,000.00
- LII $5,341,300,000.00
- Revenue This Year
- BIIB N/A
- LII $3.42
- Revenue Next Year
- BIIB $1.57
- LII $6.43
- P/E Ratio
- BIIB $12.65
- LII $27.20
- Revenue Growth
- BIIB N/A
- LII 7.21
- 52 Week Low
- BIIB $128.51
- LII $445.63
- 52 Week High
- BIIB $238.00
- LII $682.50
- Technical
- Relative Strength Index (RSI)
- BIIB 44.88
- LII 48.03
- Support Level
- BIIB $135.02
- LII $570.12
- Resistance Level
- BIIB $141.69
- LII $654.02
- Average True Range (ATR)
- BIIB 4.00
- LII 17.97
- MACD
- BIIB 0.04
- LII 4.58
- Stochastic Oscillator
- BIIB 59.44
- LII 55.70
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About LII Lennox International Inc.
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2023, residential HVAC was 68% of sales and commercial HVAC and Heatcraft refrigeration was 32% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.